Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential

Herranz, 2003, Cholecystokinin antagonists: pharmacological and therapeutic potential, Med Res Rev, 23, 559, 10.1002/med.10042 de Tullio, 2000, Therapeutic and chemical developments of cholecystokinin receptor ligands, Expert Opin Invest Drugs, 9, 129, 10.1517/13543784.9.1.129 Berna, 2007, Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases, Curr Top Med Chem, 7, 1211, 10.2174/156802607780960519 Jensen, 1996, CCKB-gastrin receptor antagonists. Recent advances and potential uses in gastric secretory disorders, Yale J Biol Med, 69, 245 Kalindjian, 2007, Strategies for the design of non-peptide CCK2 receptor agonist and antagonist ligand, Curr Top Med Chem, 7, 1195, 10.2174/156802607780960500 Garcia-Lopez, 2007, Strategies for design of non peptide CCK1R agonist/antagonist ligands, Curr Top Med Chem, 7, 1180, 10.2174/156802607780960537 de Tullio, 1999, Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists), Curr Med Chem, 6, 433, 10.2174/0929867306666220330183253 Szewczyk, 2003, CCK1R agonists: a promising target for the pharmacological treatment of obesity, Curr Top Med Chem, 3, 837, 10.2174/1568026033452258 Noble, 2007, Pharmacology of CCKRs and SAR studies of peptidic analog ligands, Curr Top Med Chem, 7, 1173, 10.2174/156802607780960447 Rehfeld, 2004, Clinical endocrinology and metabolism. Cholecystokinin, Best Pract Res Clin Endocrinol Metab, 18, 569, 10.1016/j.beem.2004.07.002 Dufresne, 2006, Cholecystokinin and gastrin receptors, Physiol Rev, 86, 805, 10.1152/physrev.00014.2005 McDonald, 2007, Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion, J Med Chem, 50, 3101, 10.1021/jm070139l Dockray, 2004, Clinical endocrinology and metabolism. Gastrin, Best Pract Res Clin Endocrinol Metab, 18, 555, 10.1016/j.beem.2004.07.003 Peter, 2006, CCK1 antagonists: are they ready for clinical use?, Dig Dis, 24, 70, 10.1159/000090310 Jensen, 2002, Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders, Pharmacol Toxicol, 91, 333, 10.1034/j.1600-0773.2002.910611.x Meyer, 1989, Role of cholecystokinin in regulation of gastrointestinal motor functions, Lancet, 2, 12, 10.1016/S0140-6736(89)90255-9 Baber, 1989, The role of CCK caerulein, and CCK antagonists in nociception, Pain, 39, 307, 10.1016/0304-3959(89)90045-6 Hebb, 2005, Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion, Prog Neuropsychopharmacol Biol Psychiatry, 29, 1225, 10.1016/j.pnpbp.2005.08.008 McCleane, 2004, Cholecystokinin antagonists a new way to improve the analgesia from old analgesics?, Curr Pharm Des, 10, 303, 10.2174/1381612043386419 Scarpignato, 1996, Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo, Aliment Pharmacol Ther, 10, 411, 10.1111/j.0953-0673.1996.00411.x Jensen, 2006, Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas, Basic Clin Pharmacol Toxicol, 98, 4, 10.1111/j.1742-7843.2006.pto_378.x Lehmann, 2003, New molecular targets for treatment of peptic ulcer disease, Drugs, 63, 1785, 10.2165/00003495-200363170-00002 Miyasaka, 2004, Enhanced gastric emptying of a liquid gastric load in mice lacking cholecystokinin-B receptor: a study of CCK-A,B, and AB receptor gene knockout mice, J Gastroenterol, 39, 319, 10.1007/s00535-003-1297-2 Dauge, 1998, CCK in anxiety and cognitive processes, Neurosci Biobehav Rev, 22, 815, 10.1016/S0149-7634(98)00011-6 Chambers, 2000, CCK-B antagonists in the control of anxiety and gastric acid secretion, Prog Med Chem, 37, 45, 10.1016/S0079-6468(08)70057-2 Berna, 2006, Serum gastrin in Zollinger–Ellison syndrome. I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature, Medicine (Baltimore), 85, 295, 10.1097/01.md.0000236956.74128.76 Ruszniewski, 2006, Well-differentiated gastric tumors/carcinomas, Neuroendocrinology, 84, 158, 10.1159/000098007 Cui, 2007, Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion, World J Gastroenterol, 13, 493, 10.3748/wjg.v13.i4.493 Qvigstad, 2004, Rebound hypersecretion after inhibition of gastric acid secretion, Basic Clin Pharmacol Toxicol, 94, 202, 10.1111/j.1742-7843.2004.pto940502.x Rehfeld, 2007, The biology of cholecystokinin and gastrin peptides, Curr Top Med Chem, 7, 1154, 10.2174/156802607780960483 Dore, 2000, Pathogenesis of duodenal ulcer disease: the rest of the story, Baillieres Best Pract Res Clin Gastroenterol, 14, 97, 10.1053/bega.1999.0061 Baldwin, 2007, CCK receptors and cancer, Curr Top Med Chem, 7, 1232, 10.2174/156802607780960492 Dockray, 2005, Gastrin: old hormone, new functions, Pflugers Arch, 449, 344, 10.1007/s00424-004-1347-5 Reubi, 2007, Targeting CCK receptors in human cancers, Curr Top Med Chem, 7, 1239, 10.2174/156802607780960546 Aly, 2004, Gastrins, cholecystokinins and gastrointestinal cancer, Biochim Biophys Acta, 1704, 1 Reubi, 2005, Candidates for peptide receptor radiotherapy today and in the future, J Nucl Med, 46, 67S Laverman, 2004, Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors, Bioconjug Chem, 15, 561, 10.1021/bc034208w Breeman, 2007, Radiolabelled regulatory peptides for imaging and therapy, Anticancer Agents Med Chem, 7, 345, 10.2174/187152007780618171 Gibril, 2004, Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors, Dig Liver Dis, 36, S106, 10.1016/j.dld.2003.11.024 Van Essen, 2007, Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours, Acta Oncol, 46, 723, 10.1080/02841860701441848 Crawley, 1983, Rapid development of tolerance to the behavioural actions of cholecystokinin, Nature, 302, 703, 10.1038/302703a0 Jensen, 1994, Receptors on pancreatic acinar cells, 1377 Witte, 1992, Characterization of the novel CCK analogs JMV-180, JMV-320, and JMV-332 in H345 cells, Peptides, 13, 1227, 10.1016/0196-9781(92)90033-Y Spanarkel, 1983, Cholecystokinin 27–32-amide. A member of a new class of cholecystokinin receptor antagonists, J Biol Chem, 258, 6746, 10.1016/S0021-9258(18)32283-X Henke, 1997, Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists, J Med Chem, 40, 2706, 10.1021/jm970265x Bignon, 1999, SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies, J Pharmacol Exp Ther, 289, 742 Castillo, 2004, Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers, Am J Physiol Gastrointest Liver Physiol, 287, G363, 10.1152/ajpgi.00074.2004 Katschinski, 2002, Loxiglumide Rotta research, IDrugs, 5, 469 Taniguchi, 1997, Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis, Jpn J Pharmacol, 73, 105, 10.1254/jjp.73.105 Gould, 1990, A model of gastric emptying in cats shows solid emptying is promoted by MK-329: a CCK antagonist, J Nucl Med, 31, 1494 Varga, 2002, Dexloxiglumide Rotta Research Lab, Curr Opin Investig Drugs, 3, 621 Trivedi, 1998, CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile, Pharm Biotechnol, 11, 481, 10.1007/0-306-47384-4_21 Semple, 1997, (3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N′-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist, J Med Chem, 40, 331, 10.1021/jm960669+ Hughes, 1990, Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity, Proc Natl Acad Sci U S A, 87, 6728, 10.1073/pnas.87.17.6728 Ziessman, 2001, Cholecystokinin cholescintigraphy: clinical indications and proper methodology, Radiol Clin North Am, 39, 997, 10.1016/S0033-8389(05)70325-0 Chen, 2001, The clinical diagnosis of chronic acalculous cholecystitis, Surgery, 130, 578, 10.1067/msy.2001.116906 Arora, 2006, Role of neuropeptides in appetite regulation and obesity — a review, Neuropeptides, 40, 375, 10.1016/j.npep.2006.07.001 Chaudhri, 2006, Gastrointestinal hormones regulating appetite, Philos Trans R Soc Lond B Biol Sci, 361, 1187, 10.1098/rstb.2006.1856 Hayes, 2006, Serotonin type-3 receptors mediate cholecystokinin-induced satiation through gastric distension, Am J Physiol Regul Integr Comp Physiol, 291, R115, 10.1152/ajpregu.00002.2006 Savastano, 2007, Intestinal nutrients elicit satiation through concomitant activation of CCK(1) and 5-HT(3) receptors, Physiol Behav, 92, 434, 10.1016/j.physbeh.2007.04.017 Geracioti, 1988, Impaired cholecystokinin secretion in bulimia nervosa, N Engl J Med, 319, 683, 10.1056/NEJM198809153191105 Jordan, 2007, Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients, Clin Pharmacol Ther Eser, 2007, Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study, Psychopharmacology (Berl), 192, 479, 10.1007/s00213-007-0738-7 Bradwejn, 2001, Cholecystokinin and panic disorder: past and future clinical research strategies, Scand J Clin Lab Invest Suppl, 234, 19, 10.1080/713783681 Schunck, 2006, Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety, Neuroimage, 31, 1197, 10.1016/j.neuroimage.2006.01.035 Radu, 2003, Pentagastrin test for anxiety — psychophysiology and personality, Psychopharmacology (Berl), 166, 139, 10.1007/s00213-002-1316-7 Shiratori, 2002, Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose–response study in Japan, Pancreas, 25, e1, 10.1097/00006676-200207000-00003 Mollereau, 2005, Opioid-modulating peptides: mechanisms of action, Curr Top Med Chem, 5, 341, 10.2174/1568026053544515 Hruby, 2006, New paradigms and tools in drug design for pain and addiction, AAPS J, 8, E450, 10.1208/aapsj080353 Wiesenfeld-Hallin, 2002, The role of spinal cholecystokinin in chronic pain states, Pharmacol Toxicol, 91, 398, 10.1034/j.1600-0773.2002.910619.x Noble, 2003, The role of CCK2 receptors in the homeostasis of the opioid system, Drugs Today (Barc), 39, 897, 10.1358/dot.2003.39.11.799467 McCleane, 2003, A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain, Neurosci Lett, 338, 151, 10.1016/S0304-3940(02)01388-5 Sramek, 1994, Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings, Anxiety, 1, 141, 10.1002/anxi.3070010308 Pande, 1999, Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder, Biol Psychiatry, 46, 860, 10.1016/S0006-3223(99)00090-6 Adams, 1995, A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder, J Clin Psychopharmacol, 15, 428, 10.1097/00004714-199512000-00007 Mather, 2007, Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy, J Nucl Med, 48, 615, 10.2967/jnumed.106.037085 Chau, 2006, Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials, Br J Cancer, 94, 1107, 10.1038/sj.bjc.6603058 Gotthardt, 2006, Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours, Endocr Relat Cancer, 13, 1203, 10.1677/erc.1.01245 Gotthardt, 2006, Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma, Eur J Nucl Med Mol Imaging, 33, 1273, 10.1007/s00259-006-0157-8 Buck, 2005, Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists, J Med Chem, 48, 6803, 10.1021/jm0490686 Jensen, 1994, Distinguishing multiple CCK receptor subtypes. Studies with guinea pig chief cells and transfected human CCK receptors, Ann N Y Acad Sci, 713, 88, 10.1111/j.1749-6632.1994.tb44055.x Morton, 2007, JNJ-17156516 (3-[5-(3,4-dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-toly l-propionate) a novel, potent and selective CCK1 receptor antagonist. In vitro and in vivo pharmacological comparison with dexloxiglumide, J Pharmacol Exp Ther, 10.1124/jpet.107.124578